{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:10:48Z","timestamp":1760523048966},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"10_Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5,15]]},"DOI":"10.2146\/ajhp130042","type":"journal-article","created":{"date-parts":[[2013,5,3]],"date-time":"2013-05-03T05:06:59Z","timestamp":1367557619000},"page":"S21-S31","source":"Crossref","is-referenced-by-count":18,"title":["Developing a management plan for oral anticoagulant reversal"],"prefix":"10.1093","volume":"70","author":[{"given":"William E.","family":"Dager","sequence":"first","affiliation":[{"name":"University of California (UC) Davis Medical Center, Sacramento; Clinical Professor of Medicine, UC Davis School of Medicine; Clinical Professor of Pharmacy, UC San Francisco School of Pharmacy; and Clinical Professor of Pharmacy, Touro School of Pharmacy, Vallejo, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041205282118800_b1-0700s21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/bmj.b1778","article-title":"Damage control resuscitation for patients with major trauma","volume":"338","author":"Jansen","year":"2009","journal-title":"BMJ"},{"key":"2019041205282118800_b2-0700s21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.7326\/0003-4819-135-6-200109180-00008","article-title":"Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin","volume":"135","author":"Hylek","year":"2001","journal-title":"Ann Intern Med"},{"key":"2019041205282118800_b3-0700s21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/TA.0b013e3181826ddf","article-title":"Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival","volume":"65","author":"Gunter","year":"2008","journal-title":"J Trauma"},{"key":"2019041205282118800_b4-0700s21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/SLA.0b013e318185a9ad","article-title":"Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients","volume":"248","author":"Holcomb","year":"2008","journal-title":"Ann Surg"},{"key":"2019041205282118800_b5-0700s21","unstructured":"Bebulin (factor IX complex) prescribing information. Westlake Village, CA: Baxter Healthcare Corporation; 2011Apr. www.baxter.com\/downloads\/healthcare_professionals\/products\/bebulin-vh_pi.pdf (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b6-0700s21","unstructured":"Profilnine SD (factor IX complex) prescribing information. Los Angeles, CA: Grifols Biologicals Inc; 2011Aug. http:\/\/www.grifolsusa.com\/Controller?_fb=pfch&pAction=_factory&file=profil9-ft.pdf&_fp=0&idPortlet=15341&idval=385714 (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b7-0700s21","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1046\/j.0007-1048.2001.03295.x","article-title":"Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients","volume":"116","author":"Preston","year":"2002","journal-title":"Br J Hematol"},{"issue":"Suppl 2","key":"2019041205282118800_b8-0700s21","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"2019041205282118800_b9-0700s21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin\u2014fourth edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br J Haematol"},{"key":"2019041205282118800_b10-0700s21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.5694\/j.1326-5377.2004.tb06407.x","article-title":"Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis","volume":"181","author":"Baker","year":"2004","journal-title":"Med J Aust"},{"key":"2019041205282118800_b11-0700s21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1345\/aph.1Q588","article-title":"Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal","volume":"46","author":"Baggs","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2019041205282118800_b12-0700s21","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1161\/STROKEAHA.112.661454","article-title":"Clinical experience with three-factor prothrombin complex concentrate to reverse warfarin anticoagulation in intracranial hemorrhage","volume":"43","author":"Switzer","year":"2012","journal-title":"Stroke"},{"key":"2019041205282118800_b13-0700s21","unstructured":"Beriplex P\/N summary of product characteristics. Marburg, Germany: CSL Behring; 2011Jul. www.medicines.org.uk\/EMC\/medicine\/21147\/SPC\/Beriplex+P+N+250+%26+500+IU\/ (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b14-0700s21","unstructured":"Octapharma USA press release. Octapharma USA focuses on urgent surgeries as FDA approves Octaplex for fast track development. Mar12, 2010. www.octapharma.com\/index.php?id=33&L=0&tx_ttnews%5Btt_news%5D=51&cHash=12e5f6621c0201b7c5deb95bd5e0b38d (accessed 14 Jan 2013)."},{"key":"2019041205282118800_b15-0700s21","unstructured":"Clinicaltrials.gov database. Efficacy and safety study of BERIPLEX\u00ae P\/N compared with plasma in patients with acute major bleeding caused by anticoagulant therapy. Last updated April 3, 2012. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00708435 (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b16-0700s21","unstructured":"Sarode R , MillingTJ, RefaaiMA. Integrated safety analysis of a 4-factor prothrombin complex concentrate versus plasma in phase III clinical trials. Poster presented at Thrombosis and Hemostasis Summit of North America, Chicago, IL; 2012 May 4. http:\/\/cdn.f1000.com\/posters\/docs\/249931755 (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b17-0700s21","unstructured":"CSL Behring news release. CSL Behring data shows 4-factor prothrombin complex concentrate is as effective and a more rapid treatment for vitamin K antagonist reversal than current standard of care. May04, 2012. www.cslbehring.com\/s1\/cs\/enco\/1151517263302\/news\/1255928833642\/prdetail.htm (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b18-0700s21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1538-7836.2006.01815.x","article-title":"Urgent reversal of warfarin with prothrombin complex concentrate","volume":"4","author":"Lankiewicz","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2019041205282118800_b19-0700s21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12245-009-0125-8","article-title":"Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy","volume":"2","author":"W\u00f3jcik","year":"2009","journal-title":"Int J Emerg Med"},{"key":"2019041205282118800_b20-0700s21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.wneu.2010.06.030","article-title":"Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII","volume":"74","author":"Pinner","year":"2010","journal-title":"World Neurosurg"},{"key":"2019041205282118800_b21-0700s21","unstructured":"NovoSeven RT (coagulation factor VIIa [recombinant] prescribing information. Princeton, NJ: Novo Nordisk Inc.; 2012Jan. www.novo-pi.com\/novosevenrt.pdf (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b22-0700s21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1553-2712.2010.00666.x","article-title":"The efficacy of factor VIIa in emergency department patients with warfarin use and traumatic intracranial hemorrhage","volume":"17","author":"Nishijima","year":"2010","journal-title":"Acad Emerg Med"},{"key":"2019041205282118800_b23-0700s21","first-page":"123","article-title":"Anticoagulation reversal","volume-title":"Anticoagulation therapy: a point-of-care guide","author":"Dougherty","year":"2011"},{"key":"2019041205282118800_b24-0700s21","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1592\/phco.26.8.1091","article-title":"Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin","volume":"26","author":"Dager","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2019041205282118800_b25-0700s21","first-page":"133","article-title":"Essential warfarin knowledge","volume-title":"Managing anticoagulation patients in the hospital","author":"Neel","year":"2007"},{"key":"2019041205282118800_b26-0700s21","unstructured":"AquaMephyton (phytonadione, aqueous colloidal solution of vitamin K) prescribing information. Whitehouse Station, NJ: Merck & Co., Inc.; 2002Feb. www.scribd.com\/doc\/33874512\/Merck-Vitamin-K-Package-Insert-Aquamephyton-PI (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b27-0700s21","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1081-1206(10)62042-X","article-title":"The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review","volume":"89","author":"Riegert-Johnson","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2019041205282118800_b28-0700s21","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1345\/aph.1R497","article-title":"Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute\/critical care setting","volume":"46","author":"Tsu","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2019041205282118800_b29-0700s21","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1345\/aph.1Q288","article-title":"Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects","volume":"45","author":"Dager","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2019041205282118800_b30-0700s21","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","article-title":"Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal","volume":"43","author":"Dowlatshahi","year":"2012","journal-title":"Stroke"},{"key":"2019041205282118800_b31-0700s21","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/0310057X1003800310","article-title":"Rapid reversal of coagulopathy in warfarin-related intracranial haemorrhages with prothrombin complex concentrates","volume":"38","author":"Chong","year":"2010","journal-title":"Anaesth Intensive Care"},{"key":"2019041205282118800_b32-0700s21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1423-0410.2010.01339.x","article-title":"Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study","volume":"99","author":"Demeyere","year":"2010","journal-title":"Vox Sang"},{"key":"2019041205282118800_b33-0700s21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(05)70233-6","article-title":"Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial","volume":"365","author":"Mendelow","year":"2005","journal-title":"Lancet"},{"key":"2019041205282118800_b34-0700s21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-3148.2009.00913.x","article-title":"Recombinant activated factor VII in the treatment of non-haemophilia patients: physician under-reporting of thromboembolic adverse events","volume":"19","author":"Hsia","year":"2009","journal-title":"Transfus Med"},{"key":"2019041205282118800_b35-0700s21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"key":"2019041205282118800_b36-0700s21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.thromres.2011.07.024","article-title":"Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy","volume":"129","author":"Majeed","year":"2011","journal-title":"Thromb Res"},{"key":"2019041205282118800_b37-0700s21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.thromres.2011.04.017","article-title":"PROTHROMBINEX(\u00ae)-VF (PTX-VF) usage for reversal of coagulopathy: prospective evaluation of thrombogenic risk","volume":"128","author":"Bobbitt","year":"2011","journal-title":"Thromb Res"},{"key":"2019041205282118800_b38-0700s21","article-title":"Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding","author":"Cabral","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"2019041205282118800_b39-0700s21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ajh.23254","article-title":"Prothrombin complex concentrates in emergency bleeding disorders","volume":"87","author":"Rodgers","year":"2012","journal-title":"Am J Hematol"},{"key":"2019041205282118800_b40-0700s21","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2011.11.JNS11836","article-title":"Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage","volume":"116","author":"Sarode","year":"2012","journal-title":"J Neurosurg"},{"key":"2019041205282118800_b41-0700s21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2146\/ajhp110725","article-title":"Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient","volume":"69","author":"Miyares","year":"2012","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041205282118800_b42-0700s21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.5858\/2009-0474-OA.1","article-title":"International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy","volume":"135","author":"Gulati","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"2019041205282118800_b43-0700s21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/ALN.0b013e3181ca6cfc","article-title":"Factor VII levels and international normalized ratios in the early phase of warfarin therapy","volume":"112","author":"Benzon","year":"2010","journal-title":"Anesthesiology"},{"key":"2019041205282118800_b44-0700s21","unstructured":"Pradaxa (dabigatran etexilate mesylate) prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2012May. www.pradaxa.com\/pradaxa-prescribing-information.jsp (accessed 2013 Jan 4)."},{"key":"#cr-split#-2019041205282118800_b45-0700s21.1","doi-asserted-by":"crossref","unstructured":"11. Van Ryn J, LitzenburgerT, WatermanA. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol. 2011","DOI":"10.1016\/S0735-1097(11)61130-3"},{"key":"#cr-split#-2019041205282118800_b45-0700s21.2","unstructured":"12. 57(Suppl 1):E1130. Presented at American College of Cardiology ACC.11 60th Annual Scientific Session & Expo, New Orleans, LA: Apr 5, 2011. http:\/\/content.onlinejacc.org\/article.aspx?articleid=1145540 (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b46-0700s21","first-page":"A11395","article-title":"Small molecule antidote for anticoagulants","volume-title":"Circulation","author":"Laulicht","year":"2012"},{"key":"2019041205282118800_b47-0700s21","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1540-8167.2011.02104.x","article-title":"New anticoagulants for prevention of stroke in patients with atrial fibrillation","volume":"22","author":"Viles-Gonzalez","year":"2011","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2019041205282118800_b48-0700s21","unstructured":"Xarelto (rivaroxaban) prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2012Nov. www.xareltohcp.com\/sites\/default\/files\/pdf\/xarelto_0.pdf#zoom=100 (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b49-0700s21","unstructured":"Eliquis (apixaban) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company. 2012Dec. http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf (accessed 2013 Jan 4)."},{"key":"2019041205282118800_b50-0700s21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"2019041205282118800_b51-0700s21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1525-139X.2010.00773.x","article-title":"What are the important drug use errors in dialysis patients? Pharmacokinetic and pharmacodynamic principles","volume":"23","author":"Dager","year":"2010","journal-title":"Semin Dial"},{"key":"2019041205282118800_b52-0700s21","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1345\/aph.1R081","article-title":"Safe use of hemodialysis for dabigatran removal before cardiac surgery","volume":"46","author":"Wanek","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2019041205282118800_b53-0700s21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2019041205282118800_b54-0700s21","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"Van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"2019041205282118800_b55-0700s21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"2019041205282118800_b56-0700s21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjmed.2011.10.017","article-title":"Interpretation of point-of-care INR results in patients treated with dabigatran","volume":"125","author":"Van Ryn","year":"2012","journal-title":"Am J Med"},{"key":"2019041205282118800_b57-0700s21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"key":"2019041205282118800_b58-0700s21","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"2019041205282118800_b59-0700s21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"2019041205282118800_b60-0700s21","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2011-11-393587","article-title":"Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding","volume":"119","author":"Warkentin","year":"2012","journal-title":"Blood"},{"key":"2019041205282118800_b61-0700s21","article-title":"Treatment of dabigatran-associated bleeding: case report and review of the literature","author":"Harinstein","year":"2012","journal-title":"J Pharm Pract"},{"key":"2019041205282118800_b62-0700s21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.amjopharm.2012.02.004","article-title":"Clinical challenges in a patient with dabigatran-induced fatal hemorrhage","volume":"10","author":"Cano","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"2019041205282118800_b63-0700s21","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1345\/aph.1Q747","article-title":"Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment","volume":"46","author":"Wychowski","year":"2012","journal-title":"Ann Pharmacother"},{"key":"2019041205282118800_b64-0700s21","article-title":"Reversing dabigatran in a life-threatening bleed occurring during cardiac ablation with factor eight inhibitor bypassing activity","volume-title":"Crit Care Med.","author":"Dager","year":"2013"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/10_Supplement_1\/S21\/28363782\/ajhp0s21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:43:00Z","timestamp":1644964980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/10_Supplement_1\/S21\/5112528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,15]]},"references-count":65,"journal-issue":{"issue":"10_Supplement_1","published-print":{"date-parts":[[2013,5,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp130042","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,5,15]]},"published":{"date-parts":[[2013,5,15]]}}}